Combination Chemotherapy Plus Radiation Therapy in Treating Adult Patients With Brain Cancer
Brain and Central Nervous System Tumors
About this trial
This is an interventional treatment trial for Brain and Central Nervous System Tumors focused on measuring adult medulloblastoma, adult anaplastic ependymoma, adult ependymoma, adult supratentorial primitive neuroectodermal tumor (PNET)
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed central nervous system cancer including: Medulloblastoma with either local residual disease of greater than 1 cm^2 on MRI following resection or evidence of metastases (M1-4) Other primitive neuroectodermal tumors Ependymoma with evidence of subarachnoid metastases Must have less than 1 cm of midline shift or no acute elevated intercranial pressure PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: WBC greater than 4,000/mm^3 Platelet count greater than 125,000/mm^3 Hemoglobin greater than 10 g/dL No preexisting hematologic condition that would increase toxicity or limit ability to comply with evaluations and follow-up Hepatic: Bilirubin less than 2 times upper limit of normal (ULN) SGOT less than 2 times ULN Alkaline phosphatase less than 2 times ULN No preexisting hepatic condition that would increase toxicity or limit ability to comply with evaluations and follow-up Renal: Creatinine greater than 70 mL/min No preexisting renal condition that would increase toxicity or limit ability to comply with evaluations and follow-up Pulmonary: No history of significant pulmonary disease or, if there is preexisting pulmonary disease, then DLCO greater than 60% of predicted No preexisting pulmonary condition that would increase toxicity or limit ability to comply with evaluations and follow-up Other: No preexisting psychiatric condition that would increase toxicity or limit ability to comply with evaluations and follow-up No prior or concurrent malignancies within the past 5 years except curatively treated carcinoma in situ of the cervix or basal cell or squamous cell skin cancer Not pregnant or nursing Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: No increasing doses of steroids for intracranial disease within 3 days of registration Radiotherapy: No prior radiotherapy Surgery: 10-28 days since prior surgical resection OR At least 5 days since prior biopsy
Sites / Locations
- H. Lee Moffitt Cancer Center and Research Institute
- Veterans Affairs Medical Center - Lakeside Chicago
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University
- CCOP - Carle Cancer Center
- CCOP - Cedar Rapids Oncology Project
- CCOP - Iowa Oncology Research Association
- CCOP - Wichita
- CCOP - Kalamazoo
- West Michigan Cancer Center
- CCOP - Metro-Minnesota
- Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
- Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center
- CCOP - Marshfield Clinic Research Foundation
- Medical College of Wisconsin Cancer Center